

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" B/h. Satyam Complex, Science City Road, Sola, Ahmedabad - 380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-67778000, Fax: +91-79-6777 8062

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

Part I (Rs. In Lacs)

Statement of Consolidated and Standalone Unaudited Financial Results for the Quarter and Nine Months ended on 31/12/2015

		Consolidated						Standalone					
Sr. No.	Particulars	31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/03/2015	31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/03/2015
		(Quarter Ended)	(Quarter Ended)	(Quarter Ended)	Nine Month Ended	Nine Month Ended	(Year Ended)	(Quarter Ended)	(Quarter Ended)	(Quarter Ended)	Nine Month Ended	Nine Month Ended	(Year Ended)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations												
(a)	Net Sales/Income from Operations (Net of excise duty)	10451.79	9115.96	6451.58	26891.16	18737.62	26607.45	7937.04	7485.17	5670.47	21266.60	16097.05	22325.99
(b)	Other Operating Income	344.12	419.68	301.45	1008.83	731.79	718.56	332.24	399.86	259.08	955.00	644.86	533.80
	Total income from Operations (net)	10795.91	9535.64	6753.03	27899.99	19469.41	27326.01	8269.28	7885.03	5929.55	22221.60	16741.91	22859.79
2	Expenses												
(a)	Cost of Materials consumed	1746.17	1972.30	1213.99	5173.05	4133.50	5377.70	1256.20	1627.39	1088.57	4009.19	3395.86	4349.74
(b)	Purchase of stock-in-trade	6094.63	4259.63	3151.80	13862.67	8219.47	12307.98	4506.77	3426.80	2738.20	10534.41	7010.58	9814.62
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-280.44	-14.38	99.17	-654.19	-24.69	270.55	-275.50	-78.28	65.25	-626.55	-69.77	193.49
(d)	Employee benefits expense	759.14	733.00	472.20	2059.08	1344.10	1787.09	707.32	681.17	419.59	1906.41	1191.09	1585.43
(e)	Depreciation and amortisation expense	130.50	110.65	112.31	355.19	355.63	456.81	88.50	68.65	71.00	229.19	233.25	293.01
(f)	Other expenses	1159.54	1412.20	1181.28	3825.18	3246.92	4303.57	1020.62	1310.36	1057.50	3437.64	2945.36	4072.06
	Total Expenses	9609.54	8473.40	6230.75	24620.98	17274.93	24503.70	7303.91	7036.09	5440.11	19490.29	14706.37	20308.35
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1186.37	1062.24	522.28	3279.01	2194.48	2822.31	965.37	848.94	489.44	2731.31	2035.54	2551.44
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	1186.37	1062.24	522.28	3279.01	2194.48	2822.31	965.37	848.94	489.44	2731.31	2035.54	2551.44
6	Finance Costs	201.64	187.26	170.78	587.80	548.41	837.74	155.11	141.16	120.47	447.01	407.24	634.74
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	984.73	874.98	351.50	2691.21	1646.07	1984.57	810.26	707.78	368.97	2284.30	1628.30	1916.70
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	984.73	874.98	351.50	2691.21	1646.07	1984.57	810.26	707.78	368.97	2284.30	1628.30	1916.70
10	Tax expense	338.51	204.92	99.64	720.39	364.99	480.43	296.53	164.90	88.55	619.39	342.29	439.40
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	646.22	670.06	251.86	1970.82	1281.08	1504.14	513.73	542.88	280.42	1664.91	1286.01	1477.30
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 + 12)	646.22	670.06	251.86	1970.82	1281.08	1504.14	513.73	542.88	280.42	1664.91	1286.01	1477.30
14	Share of Profit / (loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest*	1.90	1.79	-7.11	4.35	-0.01	2.93	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	644.32	668.27	258.97	1966.47	1281.09	1501.21	513.73	542.88	280.42	1664.91	1286.01	1477.30
17	Paid-up equity share capital of face value Rs.10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-----	-----	-----	-----	-----	9500.04	-----	-----	-----	-----	-----	9503.53
19 i & ii.	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each) (not annualised):												
	Basic	3.95	4.10	1.59	12.06	7.85	9.20	3.15	3.33	1.72	10.21	7.88	9.06
	Diluted	3.88	4.10	1.59	11.86	7.85	9.20	3.10	3.33	1.72	10.04	7.88	9.06

Notes:

- 1 The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at the meeting held on 11th February, 2016.
- 2 Figures for the previous periods/year are being regrouped wherever necessary.
- 3 Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- 4 Statutory Auditors has carried out limited review for the quarterly result for quarter ended 31.12.2015.
- 5 Consolidated results includes results of its two subsidiary Company.
- 6 This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

FOR LINCOLN PHARMACEUTICALS LIMITED

Place: Ahmedabad
Date: 11/02/2016

Sd/-
(MAHENDRA G. PATEL)
MANAGING DIRECTOR